A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
Completed · Phase 3 · NCT04123795
Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
At a glance
- Research payments reported, 2025
- $256,226
- U.S. investigators named
- 10
- Sites paid
- 11
- Planned or actual enrollment
- 49
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Certolizumab pegol (drug), Placebo (drug)
- Dates
- Started 2020-01-21; completion 2026-07-23
- Results posted
- Not yet
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
From ClinicalTrials.gov, last updated 2026-08-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $256,226 in research payments for this study in 2025 (28 payments).
Products named: Cimzia
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Navid Ezra, M.D. Dermatology · Thousand Oaks, CA
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Ana M. Duarte, MD Specialist · Miami, FL
- Julia Escandon Brehm, MD, PHD Dermatology · Wellington, FL
- Pearl C. Kwong, MD PHD Dermatology · Jacksonville, FL
- Amy S. Paller, MD Dermatology · Chicago, IL
- Linda F. Stein Gold, M.D. Dermatology · West Bloomfield, MI
- Jeffrey M. Weinberg, MD Dermatology · Kew Gardens, NY
- Jose R. Gonzalez Chavez, M.D. Dermatology · Santurce, PR
- Angela Y. Moore, MD, PA Dermatopathology · Arlington, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gcm Medical Group Psc $47,148
- Clinical Trials Research Institute $40,747
- Northwestern University $36,562
- Henry Ford Health Hospital, MI $31,696
- Nicklaus Children's Hospital, FL $30,860
- First Oc Dermatology Research Inc $30,116
- Henry Ford Behavioral Health Hospital $18,940
- Solutions Through Advanced Research Inc $12,101
- Forest Hills Dermatology Group PLLC $5,200
- Arlington Research Center Inc $2,191
- Elligo Health Research Inc $665
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.